These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1987300)

  • 1. The use of L-dopa and carbidopa in metastatic malignant melanoma.
    Gurney H; Coates A; Kefford R
    J Invest Dermatol; 1991 Jan; 96(1):85-7. PubMed ID: 1987300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The chemotherapy of malignant melanoma.
    Wick MM
    J Invest Dermatol; 1983 Jun; 80 Suppl():61s-62s. PubMed ID: 6854056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials.
    Mooney ME; Schmitz JM; Moeller FG; Grabowski J
    Drug Alcohol Depend; 2007 May; 88(2-3):214-23. PubMed ID: 17134849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study.
    Hoehn MM
    Arch Neurol; 1980 Mar; 37(3):146-9. PubMed ID: 7356419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of Parkinson's disease with the combination drug L-carbidopa/L-dopa. Report on a 2 years study].
    Hayek J
    Schweiz Med Wochenschr; 1977 Apr; 107(14):474-9. PubMed ID: 847450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of apomorphine and apomorphine-L-dopa-carbidopa on alcohol post-intoxication symptoms.
    Wadstein J; Ohlin H; Stenberg P
    Drug Alcohol Depend; 1978 Jul; 3(4):281-7. PubMed ID: 357128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
    Lombardo L; De la Garza R
    Arch Invest Med (Mex); 1977; 8(2):123-8. PubMed ID: 907417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
    Sweet RD; McDowell FH; Wasterlain CG; Stern PH
    Arch Neurol; 1975 Aug; 32(8):560-3. PubMed ID: 1156214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
    Hanzal F
    MMW Munch Med Wochenschr; 1976 May; 118(20):653-6. PubMed ID: 818540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing.
    Costa ER; Weinhold P; Tayrose GA; Hooker JA; Dahners LE
    J Orthop Trauma; 2006 Jul; 20(7):470-5. PubMed ID: 16891938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
    Lieberman A; Goodgold A; Jonas S; Leibowitz M
    Neurology; 1975 Oct; 25(10):911-6. PubMed ID: 1101099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric symptoms with initiation of carbidopa-levodopa treatment.
    Lin JT; Ziegler DK
    Neurology; 1976 Jul; 26(7):699-700. PubMed ID: 945518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.